Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics

...

Related Keywords

California ,United States ,Texas ,Germany ,San Carlos ,German ,Sangeeta Bhorade ,Coll Cardiol ,Shriprasadr Deshpande ,Health Resources ,Nasdaq ,Heart Transplant Program ,International Society For Heart ,Us Department Of Health ,Services Administration ,Clinical Laboratory Improvement Amendments ,Children National Hospital ,Transplantation Network ,National Institutes Of Health ,Human Services ,Natera Inc ,Prospera Heart ,Based Transplant Rejection Test ,Pediatric Transplantation ,National Institutes ,Advanced Cardiac ,National Hospital ,Lung Transplantation ,Molecular Microscope ,Diagnostic System ,Prospera Lung ,Scientific Registry ,Transplant Recipients ,Data Report ,Heart Transplant Patients ,Markets ,